CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers

[1]  E. Tolosa,et al.  LRRK2 in Parkinson disease: challenges of clinical trials , 2020, Nature Reviews Neurology.

[2]  J. Trojanowski,et al.  Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease , 2019, Acta Neuropathologica Communications.

[3]  Paolo Eusebi,et al.  CSF and blood biomarkers for Parkinson's disease , 2019, The Lancet Neurology.

[4]  H. Berendse,et al.  Erratum , 2018, Movement disorders : official journal of the Movement Disorder Society.

[5]  W. M. van der Flier,et al.  α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies , 2018, Movement disorders : official journal of the Movement Disorder Society.

[6]  B. Vissel,et al.  Therapeutic implications of how TNF links apolipoprotein E, phosphorylated tau, α‐synuclein, amyloid‐β and insulin resistance in neurodegenerative diseases , 2018, British journal of pharmacology.

[7]  W. Poewe.  Parkinson's disease and the quest for preclinical diagnosis: an interview with Professor Werner Poewe. , 2017, Neurodegenerative disease management.

[8]  David S. Park,et al.  β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease , 2017, Science.

[9]  P. Calabresi,et al.  Longitudinal changes in CSF alpha‐synuclein species reflect Parkinson's disease progression , 2016, Movement disorders : official journal of the Movement Disorder Society.

[10]  G. Halliday,et al.  Increased peripheral inflammation in asymptomatic leucine‐rich repeat kinase 2 mutation carriers , 2016, Movement disorders : official journal of the Movement Disorder Society.

[11]  E. Tolosa,et al.  Cerebrospinal fluid biomarkers and clinical features in leucine‐rich repeat kinase 2 (LRRK2) mutation carriers , 2016, Movement disorders : official journal of the Movement Disorder Society.

[12]  Takahiko Tokuda,et al.  Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease , 2016, Molecular Neurodegeneration.

[13]  G. Halliday,et al.  Inflammation is genetically implicated in Parkinson’s disease , 2015, Neuroscience.

[14]  D. Mann,et al.  Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology , 2015, Neurobiology of Disease.

[15]  V. Sossi,et al.  Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity , 2015, Acta neuropathologica communications.

[16]  D. Sulzer,et al.  MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration , 2014, Nature Communications.

[17]  Yih-Ru Wu,et al.  Genetic Variants of LRRK2 in Taiwanese Parkinson’s Disease , 2013, PloS one.

[18]  G. Halliday,et al.  An emerging role for LRRK2 in the immune system. , 2012, Biochemical Society transactions.

[19]  O. Levy,et al.  The neuropathology of genetic Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[20]  D. Standaert,et al.  LRRK2 Inhibition Attenuates Microglial Inflammatory Responses , 2012, The Journal of Neuroscience.

[21]  S. Cheon,et al.  Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's Disease , 2011, Journal of clinical neurology.

[22]  L. White,et al.  Subclinical signs in LRRK2 mutation carriers. , 2011, Parkinsonism & related disorders.

[23]  T. Tokuda,et al.  Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease , 2010, Neurology.

[24]  J. Nutt,et al.  Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[25]  M. Farrer,et al.  Genealogical studies in LRRK2-associated Parkinson's disease in central Norway. , 2010, Parkinsonism & related disorders.

[26]  E. Tolosa,et al.  Cerebrospinal tau, phospho‐tau, and beta‐amyloid and neuropsychological functions in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[27]  H. Braak,et al.  Parkinson's disease: a dual‐hit hypothesis , 2007, Neuropathology and applied neurobiology.

[28]  A. Bartels,et al.  Neuroinflammation in the pathophysiology of Parkinson's disease: Evidence from animal models to human in vivo studies with [11C]‐PK11195 PET , 2007, Movement disorders : official journal of the Movement Disorder Society.

[29]  Mathias Toft,et al.  Clinical features of LRRK2‐associated Parkinson's disease in central Norway , 2005, Annals of neurology.

[30]  J. Feldon,et al.  Genetic ablation of tumor necrosis factor‐alpha (TNF‐α) and pharmacological inhibition of TNF‐synthesis attenuates MPTP toxicity in mouse striatum , 2004, Journal of neurochemistry.

[31]  M. Schroll,et al.  Ageing, tumour necrosis factor‐alpha (TNF‐α) and atherosclerosis , 2000, Clinical and experimental immunology.

[32]  J. Trojanowski,et al.  Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. , 2015, JAMA neurology.

[33]  S. Gilman,et al.  Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.